FIELD: medicine.
SUBSTANCE: methods according to the invention consist in introducing an Aβ 16-23 fragment having an amino acid sequence KLVFFAED of 16-23 residues SEQ ID NO:1. Besides the invention concerns the Aβ 16-23 fragment and a pharmaceutical composition containing it.
EFFECT: feasible prevention and treatment of Alzheimer's disease ensured by inhibition of amyloid deposition in cerebrum.
72 cl, 2 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS OF PEPTIDE CONJUGATE AND METHODS FOR PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE | 2006 |
|
RU2406529C2 |
| PREVENTION AND TREATMENT OF CEREBRAL AMYLOID ANGIOPATHY | 2008 |
|
RU2523894C2 |
| METHOD OF USE IN THERAPY | 2010 |
|
RU2579659C2 |
| USING ANTI-AMYLOID BETA ANTIBODY IN OPHTHALMIC DISEASES | 2008 |
|
RU2604181C2 |
| PEPTIDE VACCINE FOR PREVENTION AND IMMUNOTHERAPY OF DEMENTIA OF THE ALZHEIMER'S TYPE | 2013 |
|
RU2696566C2 |
| ANTIBODY TO AMYLOID BETA | 2013 |
|
RU2651486C2 |
| HUMANISED ANTIBODY TO BETA AMYLOID | 2007 |
|
RU2498999C2 |
| METHOD OF TREATING OR PREVENTING DISEASE ASSOCIATED WITH DEPOSIT OF AMYLOID PROTEINS (VERSIONS) | 2010 |
|
RU2533806C2 |
| Aβ-PEPTIDE ANTIBODIES AND APPLICATION THEREOF | 2003 |
|
RU2341533C2 |
| PEPTIDE VACCINE FOR PREVENTION AND IMMUNOTHERAPY OF ALZHEIMER-TYPE DEMENTIA | 2013 |
|
RU2811687C2 |
